Study of Nivolumab alone or combined with Ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

This study focuses on several types of advanced solid tumors, including triple-negative breast cancer, gastric cancer, pancreatic cancer, small cell lung cancer, bladder cancer, and ovarian cancer. The purpose is to investigate how well two medications work together or separately in treating these cancers. The medications being studied are nivolumab and ipilimumab, which are drugs that help the body's immune system fight cancer cells.

The study will use two different treatment approaches. Some patients will receive nivolumab alone, while others will receive a combination of nivolumab and ipilimumab. Both medications are given through an intravenous infusion, which means they are delivered directly into a vein. The medications being tested are designed to boost the immune system's ability to detect and destroy cancer cells.

During the study, doctors will monitor how patients respond to the treatment and track any side effects that may occur. The study will look at whether tumors shrink or stop growing in response to the treatment, and how long patients survive without their cancer getting worse. This research may help develop new treatment options for patients with these types of advanced cancers.